Fact CheckerSign in

NCT06051604Completed

Mi-Helper Transnasal Cooling for Acute Treatment of Migraine

A Prospective, Double-blind, Sham-controlled, Randomized Clinical Trial to Assess the Safety, Efficacy, Tolerability, and Optimal Dose of the Mi-Helper Device for Acute Treatment of Episodic Migraine in an at Home Setting.

Source: ClinicalTrials.gov · Last updated 26 Sept 2024

Brief summary (registry, in English)

This is a prospective, double-blind, sham-controlled, randomized clinical trial . This study aims to assess the efficacy, safety, tolerability, and the optimal dose of the Mi-Helper transnasal cooling device for acute treatment of migraine in an at home setting. Adults aged 18 years to 65 years old with a diagnosis of episodic migraine (with or without aura) for at least one year (self-reported) will be recruited for this study.

Status (registry)
Completed
Study type
Interventional
Enrollment
172 (actual)
First submitted
18 Sept 2023
Start date
15 Nov 2023
Primary completion date
18 Jun 2024
Lead sponsor
CoolTech LLC
Diseases
Migraine
NCT number
NCT06051604

What you commit to

  • Study type: Interventional
  • Participants enrolled: 172
  • From 15 Nov 2023 to the primary completion date, 18 Jun 2024
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Participant using any opioid medication at the time of screening.
  • Participant has received Botox treatment, barbiturates, supraorbital or occipital nerve blocks within the last 4 weeks of screening.
  • Self-reported intolerance to intranasal therapy.
  • Self-reported sinus or intranasal surgery within the last 4 months of screening.
  • Prospective participant has participated in a migraine study or any interventional clinical study within the 6 months prior to screening.

Other illness

  • Self-reported history of 'complicated migraine or headaches' (i.e., hemiplegic migraine, ophthalmoplegic migraine, migrainous infarction, basilar migraine, post-traumatic headaches, post-concussion syndrome).
  • Self-reported diagnosis of alcohol or substance abuse disorder at the time of screening.
  • Participant with active chronic pain syndromes, such as fibromyalgia, chronic pelvic pain, or complex regional pain syndrome (CRPS); or other pain syndrome like trigeminal neuralgia.
  • Participant with severe psychiatric conditions (such as major depressive episode, bipolar disorder, major depressive disorder, schizophrenia), dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion, might interfere with study assessments.
  • Failure to adhere to or inability to complete Study App inputs and onboarding activities during the screening period. Participants who are not adherent during the screening period are not eligible for study entry.

Other

  • Participant has difficulty distinguishing his or her migraine attacks from tension-type headaches.
  • Participant has 15 or more headache days per month reported via migraine eDiary and during screening.
  • Participant lives at an altitude of 2000 meters or more above sea level.
  • Self-reported recurrent epistaxis or chronic rhinosinusitis.
  • Known or suspected pregnancy as self-reported by the prospective participant at the time of screening.
  • Prospective participant unable to fully understand the consent process and provide informed consent due to either language barriers or mental capacity.

Who the study is looking for

  • Age of 18 to 65 years, inclusive of either sex at birth.
  • Lives in the contiguous United States.
  • Self-reported to be able to read and understand English sufficiently to provide informed consent.
  • Individual has had a diagnosis of episodic migraine with or without aura over at least 1 year, self-reported during screening.
  • Individual experiences 2 to 8 migraine attacks per month documented via migraine eDiary during screening.
  • Individual is in good reported general health at the time of screening.
  • Migraine onset before 50 years of age, self-reported during screening.
  • Migraine prophylaxis medication unchanged for 4 weeks prior to study enrollment.
  • Stated willingness to comply with all study procedures and availability for the duration of the study.
  • Individuals that own a functioning smartphone device, internet connection (Wi-Fi or data plan) and are willing to download the study app.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
ObvioHealth
Coordinator of this site? Confirm its status
New YorkUnited StatesUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.